Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
December 31, 2021
Date of Report (Date of earliest event reported)
PETVIVO HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Nevada
001-40715
99-0363559
(State or other jurisdiction of
incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
5251 Edina Industrial Blvd.
Edina, Minnesota
55349
(Address of principal executive offices)
(Zip Code)
(952)405-6216
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001
PETV
The Nasdaq Stock Market LLC
Warrants to purchase Common Stock
PETVW
The Nasdaq Stock Market LLC
Item 5.08. Shareholder Director Nominations.
To the extent applicable, the information in Item 8.01 of this Form 8-K is incorporated by reference into this Item 5.08.
Item 8.01. Other Events.
The Board of Directors of PetVivo Holdings, Inc. (the "Company") determined that the Company's next Annual Meeting of Stockholders (the "Annual Meeting") will be held on March 4, 2022. The time and location of the Annual Meeting will be set forth in the Company's definitive proxy statement for the Annual Meeting to be filed with the Securities and Exchange Commission ("SEC"). Pursuant to the Company's Bylaws (the "Bylaws"), stockholders seeking to bring business before the Annual Meeting or to nominate candidates for election as directors at the Annual Meeting must deliver such proposals or nominations to the principal executive offices of the Company not later than January 12, 2022. Any stockholder proposal or director nomination must also comply with the requirements of Nevada law, the rules and regulations promulgated by the SEC and the Bylaws, as applicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PETVIVO HOLDINGS, INC.
Date: January 3, 2022
By:
/s/ John Lai
Name:
John Lai
Title:
Chief Executive Officer
Attachments
Original Link
Original Document
Permalink
Disclaimer
PetVivo Holdings Inc. published this content on 03 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 January 2022 19:48:01 UTC.
PetVivo Holdings, Inc. is a biomedical device company. The Company is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for animals. The Companyâs lead product Spryng with OsteoCushion Technology, is a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The Company is primarily engaged in the business of commercializing and licensing products in the veterinary market to treat and/or manage afflictions of companion animals, such as dogs and horses. Its products are derived from biomaterials that simulate a bodyâs cellular tissue by virtue of their reliance upon natural protein and carbohydrate compositions, which incorporate such tissue building blocks as collagen, elastin, and proteoglycans such as heparin. The Company has a pipeline of therapeutic devices for both veterinary and human clinical applications.